MetLife Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

MetLife Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,615	Closed	-$513K	–	2527
2021 Q1	$513K	Hold	13,615	–	–	﹤0.01%	1508
2020 Q4	$232K	Buy	+13,615	New	+$171K	﹤0.01%	1903
2019 Q3	–	Sell	-19,957	Closed	-$120K	–	2434
2019 Q2	$120K	Hold	19,957	–	–	﹤0.01%	2303
2019 Q1	$267K	Hold	19,957	–	–	﹤0.01%	1820
2018 Q4	$186K	Hold	19,957	–	–	﹤0.01%	1951
2018 Q3	$278K	Hold	19,957	–	–	﹤0.01%	1896
2018 Q2	$316K	Buy	19,957 +6,535	+49%	+$114K	﹤0.01%	1694
2018 Q1	$231K	Hold	13,422	–	–	﹤0.01%	1810
2017 Q4	$294K	Buy	+13,422	New	+$432K	﹤0.01%	1725

MetLife Investment Management's FPRX Position: Q2 2021 in Review

MetLife Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 13,615 shares — an estimated $513K sold.

MetLife Investment Management first reported a position in FPRX in Q4 2017 and held it in 9 quarters. The position peaked at $513K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

MetLife Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
MetLife Investment Management sold 13,615 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $513K.
MetLife Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 9 quarters.
MetLife Investment Management's Five Prime Therapeutics, Inc. position peaked at $513K in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.